Literature DB >> 34027977

SARS-CoV-2 Epidemic in the Israeli Defense Force-Lessons Learned From Our rt-PCR Screening Policy.

Adili Tsur1, Arik Furer1, Eva Avramovich1, Erez Karp1, Gilad Twig1, Tarif Bader1,2, Miki Almakias1, Noam Fink1.   

Abstract

BACKGROUND: During the SARS-CoV-2 pandemic, multiple preventative measures were used to prevent the virus from spreading in the population. The Israeli defense force deployed further means to contain the disease, including putting units in quarantine, physical distancing and using masks, gowns and disinfectants when in contact with suspected patients.
METHODS: We used reverse transcriptase-polymerase chain reaction (rt-PCR) tests to screen for patients among asymptomatic soldiers within units participating in civilian aid or in close contact with known patients, using personal protective equipment. Positive results were repeated and followed with serological testing to verify the nature of results.
RESULTS: Between April and May 2020, we screened a total of 1,453 soldiers in 13 different units. We found 11 false positive results, leading to unnecessary measures until resolution, and three true positive results (0.2%). All true positive results had unreported symptoms concomitant with SARS-CoV-2 disease. These results led to the resolution of this screening policy.
CONCLUSION: Screening asymptomatic army personnel in this setting with rt-PCR test for SARS-CoV-2 is not warranted and leads to unnecessary false positive results. Efforts should be directed at identifying symptomatic patients. © The Association of Military Surgeons of the United States 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Year:  2021        PMID: 34027977     DOI: 10.1093/milmed/usab215

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  1 in total

1.  SARS-CoV-2 Transmission in the Military during the Early Phase of the Pandemic-A Systematic Analysis.

Authors:  Sylvia Xiao Wei Gwee; Pearleen Ee Yong Chua; Junxiong Pang
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.